{
    "Trade/Device Name(s)": [
        "FreeStyle Libre 2 Flash Glucose Monitoring System"
    ],
    "Submitter Information": "Abbott Diabetes Care Inc.",
    "510(k) Number": "K193371",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN170088"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QLG",
        "NBW"
    ],
    "Summary Letter Date": "May 8, 2020",
    "Summary Letter Received Date": "May 11, 2020",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1355",
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [
        "Sensor Applicator and Sensor Pack (back of upper arm)"
    ],
    "Instrument(s)/Platform(s)": [
        "FreeStyle Libre 2 Sensor",
        "FreeStyle Libre 2 Reader"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical sensor",
        "Glucose oxidase enzymatic reaction",
        "Bluetooth Low Energy (BLE)",
        "RFID/NFC"
    ],
    "Methodologies": [
        "Amperometric measurement"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Reader"
    ],
    "Document Summary": "FDA 510(k) summary for FreeStyle Libre 2 Flash Glucose Monitoring System for integrated continuous glucose monitoring with real-time alarms for diabetes management.",
    "Indications for Use Summary": "Continuous glucose monitoring device with real time alarms for diabetes management in persons age 4 and older; intended to replace blood glucose testing for treatment decisions, detect trends, and aid therapy adjustments, with autonomous digital communication capability.",
    "fda_folder": "Clinical Chemistry"
}